43,965 Shares in PROCEPT BioRobotics Corporation $PRCT Bought by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC bought a new stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 43,965 shares of the company’s stock, valued at approximately $2,532,000. Lisanti Capital Growth LLC owned about 0.08% of PROCEPT BioRobotics at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. Nisa Investment Advisors LLC increased its stake in shares of PROCEPT BioRobotics by 32.5% in the first quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company’s stock valued at $64,000 after buying an additional 270 shares during the period. CWM LLC grew its holdings in PROCEPT BioRobotics by 40.7% during the 2nd quarter. CWM LLC now owns 1,228 shares of the company’s stock worth $71,000 after acquiring an additional 355 shares during the last quarter. Assetmark Inc. increased its position in PROCEPT BioRobotics by 5.1% in the 2nd quarter. Assetmark Inc. now owns 8,333 shares of the company’s stock valued at $480,000 after acquiring an additional 407 shares during the period. Arizona State Retirement System raised its stake in shares of PROCEPT BioRobotics by 3.2% during the first quarter. Arizona State Retirement System now owns 14,737 shares of the company’s stock valued at $859,000 after acquiring an additional 452 shares during the last quarter. Finally, ANTIPODES PARTNERS Ltd acquired a new position in shares of PROCEPT BioRobotics during the first quarter worth $30,000. 89.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on PRCT shares. BTIG Research reaffirmed a “neutral” rating on shares of PROCEPT BioRobotics in a research report on Tuesday, September 16th. Weiss Ratings restated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research report on Wednesday, October 8th. Oppenheimer raised PROCEPT BioRobotics from a “market perform” rating to an “outperform” rating and set a $60.00 price objective on the stock in a research note on Tuesday, September 2nd. Leerink Partners reissued an “outperform” rating and set a $55.00 target price on shares of PROCEPT BioRobotics in a research report on Wednesday. Finally, Truist Financial dropped their price target on shares of PROCEPT BioRobotics from $64.00 to $50.00 and set a “buy” rating on the stock in a research report on Wednesday, October 15th. Nine analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $63.30.

PROCEPT BioRobotics Trading Up 2.0%

Shares of PRCT stock opened at $31.92 on Friday. PROCEPT BioRobotics Corporation has a fifty-two week low of $29.78 and a fifty-two week high of $103.81. The company has a debt-to-equity ratio of 0.14, a quick ratio of 7.86 and a current ratio of 8.44. The stock has a 50 day simple moving average of $36.02 and a two-hundred day simple moving average of $47.62. The company has a market cap of $1.78 billion, a P/E ratio of -20.86 and a beta of 0.98.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.03. The company had revenue of $83.33 million during the quarter, compared to the consensus estimate of $80.78 million. PROCEPT BioRobotics had a negative net margin of 28.20% and a negative return on equity of 21.72%. The company’s quarterly revenue was up 42.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.40) EPS. PROCEPT BioRobotics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. Research analysts forecast that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current year.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).